Showing 41 - 60 results of 9,727 for search '(( 50 mg decrease ) OR ((( 50 ((we decrease) OR (nn decrease)) ) OR ( 5 step decrease ))))', query time: 0.60s Refine Results
  1. 41
  2. 42
  3. 43
  4. 44
  5. 45
  6. 46
  7. 47
  8. 48
  9. 49

    Image_1_Decrease in Serum Urate Level Is Associated With Loss of Visceral Fat in Male Gout Patients.tif by Zijing Ran (11429935)

    Published 2021
    “…Subjects included had all been treated with urate-lowering therapy (ULT) (febuxostat 20–80 mg/day or benzbromarone 25–50 mg/day, validated by the medical record). …”
  10. 50
  11. 51

    Uganda 2023 NCD risk factor STEPS survey data. by Ronald Kusolo (13200268)

    Published 2025
    “…The risk factor prevalences that decreased significantly were: inadequate physical activity from 5.0% in 2014 to 3.6% in 2023 (p=0.003), and current smoke tobacco use from 9.6% in 2014, to 8.3% in 2023 (p= 0.046). …”
  12. 52

    Uganda 2014 NCD risk factor STEPS survey data. by Ronald Kusolo (13200268)

    Published 2025
    “…The risk factor prevalences that decreased significantly were: inadequate physical activity from 5.0% in 2014 to 3.6% in 2023 (p=0.003), and current smoke tobacco use from 9.6% in 2014, to 8.3% in 2023 (p= 0.046). …”
  13. 53
  14. 54
  15. 55
  16. 56

    DataSheet_1_Decrease in Serum Urate Level Is Associated With Loss of Visceral Fat in Male Gout Patients.docx by Zijing Ran (11429935)

    Published 2021
    “…Subjects included had all been treated with urate-lowering therapy (ULT) (febuxostat 20–80 mg/day or benzbromarone 25–50 mg/day, validated by the medical record). …”
  17. 57

    Discovery of Novel Substituted <i>N</i>‑(4-Amino-2-chlorophenyl)-5-chloro-2-hydroxybenzamide Analogues as Potent Human Adenovirus Inhibitors by Jimin Xu (2208961)

    Published 2020
    “…Notably, among these derivatives, compound <b>15</b> showed improved anti-HAdV activity (IC<sub>50</sub> = 0.27 μM), significantly decreased cytotoxicity (CC<sub>50</sub> = 156.8 μM), and low <i>in vivo</i> toxicity (maximum tolerated dose = 150 mg/kg in hamster) as compared with niclosamide, supporting its further <i>in vivo</i> efficacy studies for the treatment of HAdV infections.…”
  18. 58
  19. 59
  20. 60